newsfilter
← Latest News
GlobeNewswire·

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. U.S. FDA accepted seladelpar NDA for priority review, and seladelpar marketing